false 0000744825 0000744825 2021-11-10 2021-11-10
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of report (Date of earliest event reported): November 10, 2021
(Exact name of registrant as specified in charter)
(State or other jurisdiction of incorporation)
(Commission File Number)
(IRS Employer Identification No.)
Two Embarcadero Center, Suite 410
San Francisco, CA
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number, including area code 415-788-5300
(Former name or former address, if changed since last report)
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
American Shared Hospital Services
Common Stock, No Par Value
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 Emerging growth company
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.
On November 10, 2021 the Company issued a press release announcing its financial results for the third quarter 2021. The full text of the press release is furnished as Exhibit 99.1 to this report. The Company does not intend for this exhibit to be incorporated by reference into future filings under the Securities Exchange Act of 1934.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits.
104                    Cover Page Interactive Data File (embedded within the Inline XBRL document)
The information in this report is summary information that is intended to be considered in the context of our SEC filings and other public announcements that we may make, by press release or otherwise, from time to time. We disclaim any current intention to revise or update the information contained in this report, although we may do so from time to time as our management believes is warranted. Any such updating may be made through the filing of other documents or reports with the SEC, through press releases or through other public disclosures.

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
American Shared Hospital Services
November 10, 2021
/s/Raymond C. Stachowiak
Raymond C. Stachowiak
Chief Executive Officer
EX-99.1 2 ex_305283.htm EXHIBIT 99.1 ex_305283.htm

Exhibit 99.1


American Shared Hospital Services Reports Third Quarter 2021 Financial Results


Reduced Costs & Other Positive Impacts from Financial Restructuring Benefiting Results


SAN FRANCISCO, CA, November 10, 2021 ‒ American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services, today announced financial results for the third quarter of 2021, ended September 30, 2021.


Third Quarter 2021 Financial Highlights



Total revenue in the third quarter was $4,099,000, a decrease of 12.2% from the comparable period in 2020. Proton therapy revenue of $1,293,000 decreased 23.4% from the third quarter of 2020 due to lower volumes offset by higher average reimbursement per fraction. Gamma Knife revenue of $2,806,000 decreased 5.9% compared to the third quarter of 2020 due to a decrease in procedures offset by an increase in average reimbursement per treatment at the Company’s retail sites. 



Total proton therapy fractions decreased 40.4% in the third quarter primarily due to the continued impact from the COVID-19 pandemic and down-time for repair of system components.



Gamma Knife procedures decreased 10.9% compared to the third quarter of 2020. The decrease was primarily due to two contract expirations offset by the acquisition of GKC Ecuador in June 2020. Gamma Knife volumes for same centers in operation increased 11.6% from Gamma Knife volumes for those same centers during the same period of the prior year.



Operating income for the third quarter of 2021 was $186,000 compared to an operating loss of $251,000 in the third quarter of 2020, a positive swing of $437,000 reflecting lower total direct operating costs and interest expense.



Net income in the third quarter was $33,000, or $0.01 per diluted share, compared to a net loss of $209,000, or $0.03 per diluted share for the same period in the prior year. Net income increased due to a decrease in depreciation expense, operating costs, selling and administrative costs and interest expense. 


Ray Stachowiak, Chief Executive Officer, commented, “AMS’ operating results continue to be positively impacted from the financial actions that we’ve taken despite the lingering impact from the COVID-19 pandemic on revenue. In the third quarter revenue decreased 12.2% year-over-year to $4.1 million, but combined with a greater reduction in direct and other costs, including interest expense, the gross margin increased 28.9% and net income was modestly positive. This was the third consecutive quarter that we reported positive operating income, which is benefiting from our year end balance sheet restructuring and the debt refinancing that we completed in April, and all of our cost reduction initiatives.”


“During the quarter we announced an agreement for business development services which will expand our sales efforts to all Federal facilities in the U.S., including all Veterans Affairs (VA) and Department of Defense (DoD) hospitals, and includes many of the most esteemed facilities throughout our country. This agreement expands our addressable market, and combined with other marketing initiatives in our plans, is expected to help AMS achieve its key goals to grow revenue and achieve sustained profitability. Supported by a strong foundation and ample financial resources, including $7.2 million in cash and a $7 million line of credit, we believe that AMS is well positioned for future growth,” concluded Mr. Stachowiak.




Financial Results for the Three Months Ended September 30, 2021


For the three months ended September 30, 2021, revenue decreased 12.2% to $4,099,000 compared to revenue of $4,670,000 for the third quarter of 2020. 


Third quarter revenue for the Company's proton therapy system installed at Orlando Health in Florida decreased 23.4% to $1,293,000 compared to revenue for the third quarter of 2020 of $1,687,000 due to lower volumes offset by a higher average reimbursement per fraction. Total proton therapy fractions in the third quarter were 973, a decrease of 40.4% compared to 1,632 proton therapy fractions in the third quarter of 2020 primarily due to the continued impact from the COVID-19 pandemic and down-time for repair of system components.


Revenue for the Company's Gamma Knife operations decreased 5.9% to $2,806,000 for the third quarter of 2021 compared to $2,983,000 for the third quarter of 2020. The decrease was due to decrease in procedures, offset by an increase in average reimbursement. The increase in average reimbursement was driven by the Company’s contract that expired in the fourth quarter of 2020, which was reimbursed at a lower rate, and an increase in the average rate at the Company’s retail sites.


Gamma Knife procedures decreased by 10.9% to 336 for the third quarter of 2021 from 377 in the same period of the prior year primarily due to the expiration of one contract in the fourth quarter of 2020 and another contract in the first quarter of 2021, offset by the acquisition of GKCE in June 2020. Gamma Knife volumes for same centers in operation increased 11.6% from Gamma Knife volumes for those same centers during the same period of the prior year.


Gross margin for the third quarter of 2021 increased 28.9% to $1,467,000, or 35.8% of revenue, compared to gross margin of $1,138,000, or 24.4% of revenue, for the third quarter of 2020.  The increase was primarily due to a 32.7% decrease in depreciation and amortization and a 26.4% decrease in other direct operating costs primarily due to the expiration of one contract in the first quarter of 2021 and a decrease in operating costs for the Company’s existing retail sites.


The decrease in depreciation and amortization was due to the expiration of one contract in the fourth quarter of 2020 and another contract in the first quarter of 2021. In addition, the Company determined some of its Gamma Knife equipment was impaired as of December 31, 2020 and the related equipment values were written off. Therefore, there was no depreciation expense incurred on this equipment for the three-month period ended September 30, 2021. These decreases were offset by a change in estimate for salvage value for nine of the Company’s Gamma Knife units implemented in the second quarter of 2021. The net effect of this change in estimate for the three-month period ended September 30, 2021, was a decrease in net income of approximately $114,000 or $0.02 per diluted share. Salvage value is based on the estimated fair value of the equipment at the end of its useful life. This change in estimate also impacts future periods.


Selling and administrative costs decreased by 1.4% to $1,119,000 for the three-month period compared to $1,135,000 for the same period in the prior year due to lower legal, accounting and tax fees. Interest expense decreased 36.2% to $162,000 compared to $254,000 for the same period in the prior year. On April 9, 2021, the Company refinanced the majority of its existing debt and finance lease portfolio at a lower effective interest rate compared to the Company's historic portfolio rate, reducing interest expense.




Operating income for the third quarter of 2021 was $186,000 compared to an operating loss of $251,000 in the third quarter of 2020, a positive swing of $437,000 reflecting lower direct operating costs and interest expense.


Net income in the third quarter was $33,000, or $0.01 per diluted share, compared to a net loss of $209,000, or $(0.03) per diluted share, for the third quarter of 2020. Fully diluted weighted average common shares outstanding were 6,123,000 and 6,049,000 for the third quarter of 2021 and 2020, respectively.


Adjusted EBITDA, a non-GAAP financial measure, was $1,562,000 for the third quarter of 2021, compared to $1,979,000 for the third quarter of 2020. The decrease was primarily due to the decrease in revenue compared to the prior period.


Financial Results for the Nine Months Ended September 30, 2021


For the nine months ended September 30, 2021, revenue decreased 2.2% to $12,939,000 compared to revenue of $13,229,000 for the first nine months of 2020. Proton therapy revenue decreased by 8.2% to $4,372,000 for the first nine months of 2021 compared to $4,764,000 for the first nine months of 2020. Total proton therapy fractions in the first nine months of 2021 were 3,313, a decrease of 28.9% compared to 4,659 proton therapy fractions in the comparable period of 2020. The decrease was primarily due to the continued impact from the COVID-19 pandemic as well as down-time for repair of equipment components during the period.


Gamma Knife revenue increased 1.9% to $8,626,000 for the first nine months of 2021 compared to $8,465,000 for the first nine months of 2020. The number of Gamma Knife procedures in the first nine months of 2021 was 1,067, a decrease of 3.3% compared to 1,103 Gamma Knife procedures in the comparable period of 2020. Gamma Knife volumes for same centers in operation increased 9.2% from Gamma Knife volumes for those same centers during the same period of the prior year.


Net loss for the first nine months of 2021 was $25,000, or $0.00 per diluted share, compared to a net loss of $827,000, or $(0.14) per diluted share, for the first nine months of 2020. The 2021 period includes a pretax loss on the extinguishment of debt of $401,000. Net income excluding the net charge of $244,000 was $219,000, or $0.04 per diluted share. Adjusted EBITDA, a non-GAAP financial measure, was $5,024,000 for the first nine months of 2021, compared to $5,238,000 for the first nine months of 2020.


Balance Sheet Highlights


At September 30, 2021, cash, cash equivalents, and restricted cash was $7,168,000, compared to $4,325,000 at December 31, 2020.  Shareholders' equity at September 30, 2021 was $23,953,000, or $4.08 per outstanding share.  This compares to shareholders' equity at December 31, 2020 of $23,650,000, or $4.08 per outstanding share.




Conference Call and Webcast Information


AMS has scheduled a conference call at 12:00 p.m. PST (3:00 p.m. EST) today. To participate, please call 1 (844) 413-3972 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call. A simultaneous Webcast of the call may be accessed through the Company's website, www.ashs.com, or at www.streetevents.com for institutional investors.


A replay of the call will be available at 1 (877) 344-7529, access code 10161791, through November 17, 2021.


About American Shared Hospital Services (NYSE American: AMS)


American Shared Hospital Services is a leading provider of turnkey technology solutions for stereotactic radiosurgery and advanced radiation therapy equipment and services. AMS is a world leader in providing Gamma Knife radiosurgery equipment, a non-invasive treatment for malignant and benign brain tumors, vascular malformations, and trigeminal neuralgia (facial pain). The Company also offers proton therapy, and the latest IGRT, IMRT and MR/LINAC systems. For more information, please visit: www.ashs.com .


Earnings Disclosure


The Centers for Medicare and Medicaid (“CMS”) have established a 2022 delivery code reimbursement rate of approximately $7,943 ($7,773 in 2021) for a Medicare Gamma Knife treatment. The approximate CMS reimbursement rates for delivery of PBRT for a simple treatment without compensation for 2022 is $554 ($543 in 2021) and $1,321 ($1,298 in 2021) for simple with compensation, intermediate and complex treatments, respectively.


Safe Harbor Statement


This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services (including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton therapy and MR/LINAC business, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risks of variability of financial results between quarters, the risks of the Gamma Knife and proton therapy businesses, the risks of developing The Operating Room for the 21st Century program, the risks of changes to CMS reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, proton therapy, and MR/LINAC businesses, the risks of the COVID-19 pandemic and its effect on the Company’s business operations and financial condition, the risk of expanding within or into new markets, the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the year ended December 31, 2020, its quarterly report on Form 10-Q for the three months ended March 31, 2021 and June 30, 2021, and the definitive Proxy Statement for the Annual Meeting of Shareholders that was held on June 25, 2021.




Non-GAAP Financial Measure


Adjusted EBITDA, the non-GAAP measure presented in this press release and supplementary information, is not a measure of performance under the accounting principles generally accepted in the United States ("GAAP").  This non-GAAP financial measure has limitations as an analytical tool, including that it does not have a standardized meaning. When assessing our operating performance, this non-GAAP financial measure should not be considered a substitute for, and investors should also consider, income (loss) before income taxes, income (loss) from operations, net income (loss) attributable to the Company, earnings (loss) per share and other measures of performance as defined by GAAP as indicators of the Company's performance or profitability.


EBITDA is a non-GAAP financial measure representing our (loss) earnings before interest expense, income tax (benefit) expense, depreciation, and amortization. We define Adjusted EBITDA as net (loss) income before interest expense, income tax (benefit) expense, depreciation and amortization expense, stock-based compensation expense, loss on extinguishment of debt and acquisition transaction costs.


We use this non-GAAP financial measure as a means to evaluate period-to-period comparisons. Our management believes that this non-GAAP financial measure provides meaningful supplemental information regarding our performance by excluding certain expenses and charges that may not be indicative of the operating results of our recurring core business, such as loss on extinguishment of debt, acquisition transaction costs, and stock-based compensation expense.  We believe that both management and investors benefit from referring to this non-GAAP financial measure in assessing our performance.




American Shared Hospital Services
Ray Stachowiak
Chief Executive Officer


Investor Relations
PCG Advisory
Stephanie Prince
P: (646) 863-6341



- Tables Follow -









Summary of Operations Data


Three months ended September 30,


Nine months ended September 30,











    4,099,000       4,670,000       12,939,000       13,229,000  

Costs of revenue

    2,632,000       3,532,000       8,431,000       9,790,000  

Gross margin

    1,467,000       1,138,000       4,508,000       3,439,000  

Selling & administrative expense

    1,119,000       1,135,000       3,293,000       3,556,000  

Interest expense

    162,000       254,000       587,000       803,000  

Operating income (loss)

    186,000       (251,000 )     628,000       (920,000 )

(Loss) on extinguishment of debt

    -       -       (401,000 )     -  

Interest and other (loss) income

    (1,000 )     3,000       -       7,000  

Income (loss) before income taxes

    185,000       (248,000 )     227,000       (913,000 )

Income tax expense (benefit)

    17,000       (34,000 )     (1,000 )     (192,000 )

Net income (loss)

  $ 168,000     $ (214,000 )   $ 228,000     $ (721,000 )

Less: Net (income) loss attributable to non-controlling interest

    (135,000 )     5,000       (253,000 )     (106,000 )

Net income (loss) attributable to American Shared Hospital Services

  $ 33,000     $ (209,000 )   $ (25,000 )   $ (827,000 )

Earnings (loss) per common share:



  $ 0.01     $ (0.03 )   $ 0.00     $ (0.14 )

Assuming dilution

  $ 0.01     $ (0.03 )   $ 0.00     $ (0.14 )

Weighted Average Shares Outstanding:



    6,103,000       6,049,000       5,824,000       6,060,000  

Assuming dilution

    6,123,000       6,049,000       5,824,000       6,060,000  





American Shared Hospital Services                                                 

Balance Sheet Data



Balance Sheet Data






Cash, cash equivalents and restricted cash

  $ 7,168,000     $ 4,325,000  

Current assets

  $ 13,791,000     $ 10,850,000  

Total assets

  $ 44,147,000     $ 43,653,000  

Current liabilities

  $ 4,582,000     $ 12,380,000  

Shareholders' equity

  $ 23,953,000     $ 23,650,000  




American Shared Hospital Services                                                 

Adjusted EBITDA



















Net Income (Loss)

  $ 33,000     $ (209,000 )   $ (25,000 )     (827,000 )

Plus:   Income Tax (Benefit) Expense

    17,000       (34,000 )     (1,000 )     (192,000 )

Interest Expense

    162,000       254,000       587,000       803,000  

Depreciation and Amortization Expense

    1,241,000       1,819,000       3,750,000       5,103,000  

Stock-Based Compensation Expense

    109,000       80,000       312,000       189,000  

Loss on Extinguishment of Debt

    -       -       401,000       -  

Acquisition Transaction Costs

    -       69,000       -       162,000  

Adjusted EBITDA

    1,562,000       1,979,000       5,024,000       5,238,000  


EX-101.SCH 3 ams-20211110.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink EX-101.DEF 4 ams-20211110_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 5 ams-20211110_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity [Domain] Legal Entity [Axis] Document Information [Line Items] Document Information [Table] Document, Type Document, Period End Date Entity, Registrant Name Entity, Incorporation, State or Country Code Entity, File Number Entity, Tax Identification Number Entity, Address, Address Line One Entity, Address, City or Town Entity, Address, State or Province Entity, Address, Postal Zip Code City Area Code Local Phone Number Title of 12(b) Security Trading Symbol Security Exchange Name Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Entity, Emerging Growth Company Amendment Flag Entity, Central Index Key EX-101.PRE 6 ams-20211110_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 7 asha20211109_8k_htm.xml IDEA: XBRL DOCUMENT 0000744825 2021-11-10 2021-11-10 false 0000744825 8-K 2021-11-10 AMERICAN SHARED HOSPITAL SERVICES CA 1-08789 94-2918118 Two Embarcadero Center, Suite 410 San Francisco CA 94111 415 788-5300 Common Stock AMS NYSE false false false false false XML 8 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document And Entity Information
Nov. 10, 2021
Document Information [Line Items]  
Document, Type 8-K
Document, Period End Date Nov. 10, 2021
Entity, Incorporation, State or Country Code CA
Entity, File Number 1-08789
Entity, Tax Identification Number 94-2918118
Entity, Address, Address Line One Two Embarcadero Center, Suite 410
Entity, Address, City or Town San Francisco
Entity, Address, State or Province CA
Entity, Address, Postal Zip Code 94111
City Area Code 415
Local Phone Number 788-5300
Title of 12(b) Security Common Stock
Trading Symbol AMS
Security Exchange Name NYSE
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity, Emerging Growth Company false
Amendment Flag false
Entity, Central Index Key 0000744825
EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.ams.com/20211110/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false All Reports Book All Reports asha20211109_8k.htm ams-20211110.xsd ams-20211110_def.xml ams-20211110_lab.xml ams-20211110_pre.xml ex_305283.htm http://xbrl.sec.gov/dei/2021 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "asha20211109_8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "definitionLink": { "local": [ "ams-20211110_def.xml" ] }, "inline": { "local": [ "asha20211109_8k.htm" ] }, "labelLink": { "local": [ "ams-20211110_lab.xml" ] }, "presentationLink": { "local": [ "ams-20211110_pre.xml" ] }, "schema": { "local": [ "ams-20211110.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "https://xbrl.sec.gov/dei/2021/dei-2021.xsd", "https://xbrl.sec.gov/country/2021/country-2021.xsd", "https://xbrl.sec.gov/sic/2021/sic-2021.xsd", "https://xbrl.sec.gov/currency/2021/currency-2021.xsd", "https://xbrl.sec.gov/exch/2021/exch-2021.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd" ] } }, "elementCount": 26, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2021": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "ams", "nsuri": "http://www.ams.com/20211110", "report": { "R1": { "firstAnchor": { "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "asha20211109_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "role": "http://www.ams.com/20211110/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "div", "td", "tr", "tbody", "table", "body", "html" ], "baseRef": "asha20211109_8k.htm", "contextRef": "d20218K", "decimals": null, "first": true, "lang": "en-US", "name": "dei:EntityRegistrantName", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2021", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document, Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document, Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity, Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity, Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity, Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity, Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity, Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity, Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity, File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity, Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity, Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity, Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2021", "presentation": [ "http://www.ams.com/20211110/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" } }, "version": "2.1" } ZIP 15 0001437749-21-026072-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-21-026072-xbrl.zip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end